Chimerix (NASDAQ:CMRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on the stock. HC Wainwright reissued a “neutral” rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush restated a “neutral” rating and set a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Price Performance

Shares of CMRX opened at $8.54 on Wednesday. The firm has a 50 day simple moving average of $7.39 and a two-hundred day simple moving average of $3.97. The company has a market cap of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. Chimerix has a one year low of $0.75 and a one year high of $8.55.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. On average, analysts expect that Chimerix will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

A number of hedge funds have recently bought and sold shares of CMRX. Stoneridge Investment Partners LLC grew its position in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 8,134 shares during the period. Bender Robert & Associates bought a new stake in Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix in the 4th quarter valued at $59,000. Jane Street Group LLC purchased a new stake in shares of Chimerix in the fourth quarter valued at about $62,000. Finally, Diadema Partners LP bought a new position in shares of Chimerix in the fourth quarter valued at approximately $101,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.